肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

中国NMPA接受PD-1 /TGF-β双功能融合蛋白临床试验的申请

2021-03-08 Allan MedSci原创

NMPAPD-1 /TGF-β双功能融合蛋白JS201
关注

JS201是君实生物使用其专有技术开发的一种双功能融合蛋白，可以同时靶向PD-1和TGF-β（转化生长因子-β）。

最近，上海君实生物科技有限公司（Junshi Biosciences）宣布其PD-1 /TGF-β双功能融合蛋白JS201注射液（JS201）的临床试验申请已被中国国家药品管理局（NMPA）接受。

JS201是君实生物使用其专有技术开发的一种双功能融合蛋白，可以同时靶向PD-1和TGF-β（转化生长因子-β）。JS201是首个获准在中国进行临床试验的靶向PD-1/TGF-β的产品。JS201可有效阻断PD-1和TGF-β的免疫抑制途径，提高肿瘤微环境中的免疫调节作用，从而增强患者免疫系统对肿瘤细胞的杀伤作用、减少免疫逃逸和耐药性的发生。

Junshi Biosciences是中国第一家获得抗PD-1单克隆抗体销售许可的中国制药公司。其针对实体瘤的人类首创抗BTLA抗体是世界上第一个被FDA和NMPA批准用于临床试验的抗体。其抗PCSK9单克隆抗体是NMPA在中国批准的第一项临床试验。2020年初，Junshi Biosciences与中国科学院微生物研究所和礼来公司共同开发了JS016，这是中国首个针对SARS-CoV-2的完全人源单克隆抗体，现已进入临床试验。

目前，Junshi Biosciences在美国（旧金山和马里兰州）和中国（上海、苏州、北京和广州）拥有2,000多名员工。

 

原始出处：

https://www.firstwordpharma.com/node/1807148?tsid=4

评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1987956, encodeId=7153198e95649, content=<a href='/topic/show?id=00d88886e5e' target=_blank style='color:#2F92EE;'>#融合蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88867, encryptionId=00d88886e5e, topicName=融合蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Wed Jun 02 05:43:06 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003407, encodeId=0c8f100340eb8, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKFGucAbiblxRaM4pguwtZW1b9ht4VM4eOCaMop2XgRhYA3YnCbDvkYqNKBrQMqfuicPfIjWq70C74w/132, createdBy=7e5a2499123, createdName=lily81713, createdTime=Wed Jul 28 19:24:08 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003404, encodeId=45fb1003404ca, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKFGucAbiblxRaM4pguwtZW1b9ht4VM4eOCaMop2XgRhYA3YnCbDvkYqNKBrQMqfuicPfIjWq70C74w/132, createdBy=7e5a2499123, createdName=lily81713, createdTime=Wed Jul 28 19:22:46 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035912, encodeId=7d47203591217, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Tue Dec 07 15:43:06 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947131, encodeId=7d6694e1310f, content=临床试验申请的接受, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Wed Mar 10 14:59:04 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441391, encodeId=049e1441391b6, content=<a href='/topic/show?id=58dd1e34591' target=_blank style='color:#2F92EE;'>#TGF-β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17345, encryptionId=58dd1e34591, topicName=TGF-β)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=496f4824495, createdName=ms6980045490879608, createdTime=Wed Mar 10 12:43:06 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525568, encodeId=49cc15255685c, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Wed Mar 10 12:43:06 CST 2021, time=2021-03-10, status=1, ipAttribution=)]
    2021-06-02 meichuangyi

    #融合蛋白#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1987956, encodeId=7153198e95649, content=<a href='/topic/show?id=00d88886e5e' target=_blank style='color:#2F92EE;'>#融合蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88867, encryptionId=00d88886e5e, topicName=融合蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Wed Jun 02 05:43:06 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003407, encodeId=0c8f100340eb8, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKFGucAbiblxRaM4pguwtZW1b9ht4VM4eOCaMop2XgRhYA3YnCbDvkYqNKBrQMqfuicPfIjWq70C74w/132, createdBy=7e5a2499123, createdName=lily81713, createdTime=Wed Jul 28 19:24:08 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003404, encodeId=45fb1003404ca, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKFGucAbiblxRaM4pguwtZW1b9ht4VM4eOCaMop2XgRhYA3YnCbDvkYqNKBrQMqfuicPfIjWq70C74w/132, createdBy=7e5a2499123, createdName=lily81713, createdTime=Wed Jul 28 19:22:46 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035912, encodeId=7d47203591217, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Tue Dec 07 15:43:06 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947131, encodeId=7d6694e1310f, content=临床试验申请的接受, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Wed Mar 10 14:59:04 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441391, encodeId=049e1441391b6, content=<a href='/topic/show?id=58dd1e34591' target=_blank style='color:#2F92EE;'>#TGF-β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17345, encryptionId=58dd1e34591, topicName=TGF-β)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=496f4824495, createdName=ms6980045490879608, createdTime=Wed Mar 10 12:43:06 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525568, encodeId=49cc15255685c, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Wed Mar 10 12:43:06 CST 2021, time=2021-03-10, status=1, ipAttribution=)]
    2021-07-28 lily81713

    好

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1987956, encodeId=7153198e95649, content=<a href='/topic/show?id=00d88886e5e' target=_blank style='color:#2F92EE;'>#融合蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88867, encryptionId=00d88886e5e, topicName=融合蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Wed Jun 02 05:43:06 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003407, encodeId=0c8f100340eb8, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKFGucAbiblxRaM4pguwtZW1b9ht4VM4eOCaMop2XgRhYA3YnCbDvkYqNKBrQMqfuicPfIjWq70C74w/132, createdBy=7e5a2499123, createdName=lily81713, createdTime=Wed Jul 28 19:24:08 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003404, encodeId=45fb1003404ca, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKFGucAbiblxRaM4pguwtZW1b9ht4VM4eOCaMop2XgRhYA3YnCbDvkYqNKBrQMqfuicPfIjWq70C74w/132, createdBy=7e5a2499123, createdName=lily81713, createdTime=Wed Jul 28 19:22:46 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035912, encodeId=7d47203591217, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Tue Dec 07 15:43:06 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947131, encodeId=7d6694e1310f, content=临床试验申请的接受, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Wed Mar 10 14:59:04 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441391, encodeId=049e1441391b6, content=<a href='/topic/show?id=58dd1e34591' target=_blank style='color:#2F92EE;'>#TGF-β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17345, encryptionId=58dd1e34591, topicName=TGF-β)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=496f4824495, createdName=ms6980045490879608, createdTime=Wed Mar 10 12:43:06 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525568, encodeId=49cc15255685c, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Wed Mar 10 12:43:06 CST 2021, time=2021-03-10, status=1, ipAttribution=)]
    2021-07-28 lily81713

    很好

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1987956, encodeId=7153198e95649, content=<a href='/topic/show?id=00d88886e5e' target=_blank style='color:#2F92EE;'>#融合蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88867, encryptionId=00d88886e5e, topicName=融合蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Wed Jun 02 05:43:06 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003407, encodeId=0c8f100340eb8, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKFGucAbiblxRaM4pguwtZW1b9ht4VM4eOCaMop2XgRhYA3YnCbDvkYqNKBrQMqfuicPfIjWq70C74w/132, createdBy=7e5a2499123, createdName=lily81713, createdTime=Wed Jul 28 19:24:08 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003404, encodeId=45fb1003404ca, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKFGucAbiblxRaM4pguwtZW1b9ht4VM4eOCaMop2XgRhYA3YnCbDvkYqNKBrQMqfuicPfIjWq70C74w/132, createdBy=7e5a2499123, createdName=lily81713, createdTime=Wed Jul 28 19:22:46 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035912, encodeId=7d47203591217, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Tue Dec 07 15:43:06 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947131, encodeId=7d6694e1310f, content=临床试验申请的接受, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Wed Mar 10 14:59:04 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441391, encodeId=049e1441391b6, content=<a href='/topic/show?id=58dd1e34591' target=_blank style='color:#2F92EE;'>#TGF-β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17345, encryptionId=58dd1e34591, topicName=TGF-β)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=496f4824495, createdName=ms6980045490879608, createdTime=Wed Mar 10 12:43:06 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525568, encodeId=49cc15255685c, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Wed Mar 10 12:43:06 CST 2021, time=2021-03-10, status=1, ipAttribution=)]
    2021-12-07 changhe713

    #TGF#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1987956, encodeId=7153198e95649, content=<a href='/topic/show?id=00d88886e5e' target=_blank style='color:#2F92EE;'>#融合蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88867, encryptionId=00d88886e5e, topicName=融合蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Wed Jun 02 05:43:06 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003407, encodeId=0c8f100340eb8, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKFGucAbiblxRaM4pguwtZW1b9ht4VM4eOCaMop2XgRhYA3YnCbDvkYqNKBrQMqfuicPfIjWq70C74w/132, createdBy=7e5a2499123, createdName=lily81713, createdTime=Wed Jul 28 19:24:08 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003404, encodeId=45fb1003404ca, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKFGucAbiblxRaM4pguwtZW1b9ht4VM4eOCaMop2XgRhYA3YnCbDvkYqNKBrQMqfuicPfIjWq70C74w/132, createdBy=7e5a2499123, createdName=lily81713, createdTime=Wed Jul 28 19:22:46 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035912, encodeId=7d47203591217, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Tue Dec 07 15:43:06 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947131, encodeId=7d6694e1310f, content=临床试验申请的接受, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Wed Mar 10 14:59:04 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441391, encodeId=049e1441391b6, content=<a href='/topic/show?id=58dd1e34591' target=_blank style='color:#2F92EE;'>#TGF-β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17345, encryptionId=58dd1e34591, topicName=TGF-β)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=496f4824495, createdName=ms6980045490879608, createdTime=Wed Mar 10 12:43:06 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525568, encodeId=49cc15255685c, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Wed Mar 10 12:43:06 CST 2021, time=2021-03-10, status=1, ipAttribution=)]
    2021-03-10 科研科研科研

    临床试验申请的接受

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1987956, encodeId=7153198e95649, content=<a href='/topic/show?id=00d88886e5e' target=_blank style='color:#2F92EE;'>#融合蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88867, encryptionId=00d88886e5e, topicName=融合蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Wed Jun 02 05:43:06 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003407, encodeId=0c8f100340eb8, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKFGucAbiblxRaM4pguwtZW1b9ht4VM4eOCaMop2XgRhYA3YnCbDvkYqNKBrQMqfuicPfIjWq70C74w/132, createdBy=7e5a2499123, createdName=lily81713, createdTime=Wed Jul 28 19:24:08 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003404, encodeId=45fb1003404ca, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKFGucAbiblxRaM4pguwtZW1b9ht4VM4eOCaMop2XgRhYA3YnCbDvkYqNKBrQMqfuicPfIjWq70C74w/132, createdBy=7e5a2499123, createdName=lily81713, createdTime=Wed Jul 28 19:22:46 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035912, encodeId=7d47203591217, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Tue Dec 07 15:43:06 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947131, encodeId=7d6694e1310f, content=临床试验申请的接受, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Wed Mar 10 14:59:04 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441391, encodeId=049e1441391b6, content=<a href='/topic/show?id=58dd1e34591' target=_blank style='color:#2F92EE;'>#TGF-β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17345, encryptionId=58dd1e34591, topicName=TGF-β)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=496f4824495, createdName=ms6980045490879608, createdTime=Wed Mar 10 12:43:06 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525568, encodeId=49cc15255685c, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Wed Mar 10 12:43:06 CST 2021, time=2021-03-10, status=1, ipAttribution=)]
    2021-03-10 ms6980045490879608

    #TGF-β#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1987956, encodeId=7153198e95649, content=<a href='/topic/show?id=00d88886e5e' target=_blank style='color:#2F92EE;'>#融合蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88867, encryptionId=00d88886e5e, topicName=融合蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Wed Jun 02 05:43:06 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003407, encodeId=0c8f100340eb8, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKFGucAbiblxRaM4pguwtZW1b9ht4VM4eOCaMop2XgRhYA3YnCbDvkYqNKBrQMqfuicPfIjWq70C74w/132, createdBy=7e5a2499123, createdName=lily81713, createdTime=Wed Jul 28 19:24:08 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003404, encodeId=45fb1003404ca, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKFGucAbiblxRaM4pguwtZW1b9ht4VM4eOCaMop2XgRhYA3YnCbDvkYqNKBrQMqfuicPfIjWq70C74w/132, createdBy=7e5a2499123, createdName=lily81713, createdTime=Wed Jul 28 19:22:46 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035912, encodeId=7d47203591217, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Tue Dec 07 15:43:06 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947131, encodeId=7d6694e1310f, content=临床试验申请的接受, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Wed Mar 10 14:59:04 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441391, encodeId=049e1441391b6, content=<a href='/topic/show?id=58dd1e34591' target=_blank style='color:#2F92EE;'>#TGF-β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17345, encryptionId=58dd1e34591, topicName=TGF-β)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=496f4824495, createdName=ms6980045490879608, createdTime=Wed Mar 10 12:43:06 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525568, encodeId=49cc15255685c, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Wed Mar 10 12:43:06 CST 2021, time=2021-03-10, status=1, ipAttribution=)]
    2021-03-10 licz0427

    #融合#

    0

相关资讯

汇总：2020年NMPA共批准创新药48个，接近FDA水平

2020年，国家药品监督管理局（NMPA）共批准48个新药，其中国产新药20个，进口新药28个。从药物类型上看，包括28个化药，15个生物药，3个中药，2个疫苗。

不受制NMPA加速创新审评，药审、械审大湾区分中心挂牌成立

国家药品监督管理局（NMPA）药品审评检查大湾区分中心、医疗器械技术审评检查大湾区分中心正式挂牌。

NMPA批准针对痴呆症的18F-APN-1607 Tau PET成像示踪剂的III期临床试验

中国国家药品监督管理局（NMPA）已批准启动III期临床试验，以评估APRINOIA的正电子发射断层扫描（PET）成像示踪剂18F-APN-1607。

Sirtex Medical和China Grand Pharmaceutical宣布SIR-Spheres Y-90树脂微球获得NMPA认可

SIR-Spheres®Y-90树脂微球的新药申请（NDA）已获得中国NMPA的批准。

中国NMPA接受Envafolimab（KN035）治疗MSI-H / dMMR晚期实体瘤的NDA

生物制药公司TRACON今天宣布，中国国家药品监督管理局（NMPA）已经接受Envafolimab（KN035）治疗MSI-H / dMMR晚期实体瘤的新药申请（NDA）。

中国类风湿关节炎患者的福音！阿达木单抗生物类似物SULINNO在中国获准上市

信达生物（Innovent Biologics）今日宣布，SULINNO（重组人抗TNF-α单克隆抗体注射剂，阿达木单抗生物类似物）已获得NMPA的正式批准。

拓展阅读

刘嘉教授：PD-1在急性HBV感染免疫调控中的深度探索

第34届亚太肝病学会年会举行，刘嘉教授分享PD-1在急慢性HBV感染中的作用，指出其在急性感染中促进HBV特异性CD8+T细胞扩增，且在不同免疫环境下作用不同，还谈及研究价值及未来探索方向。

Cell Metab | 单细胞图谱揭示抗PD-1治疗非小细胞肺癌的免疫异质性

本研究通过构建大规模单细胞图谱，揭示了抗PD-1治疗NSCLC患者中免疫微环境的异质性。研究识别出5种不同的TIME亚型，每种亚型具有独特的免疫细胞组成和治疗反应特征。

读书报告 | PD1抗体单药辅助治疗黑色素瘤人群和亚型的效益/毒性和复发模式的差异

北京大学肿瘤医院斯璐教授课题组回顾分析多中心队列不同种族背景和黑色素瘤亚型患者之间抗PD-1单药治疗生存率、复发模式及不良反应的差异性。

高风险手术困难乳腺癌怎么办？信使RNA联合PD-1让80%患者对治疗产生应答！

最近发布在《JAMA Onco》杂志的一项研究探索了将小RNA和免疫治疗联合，以增强肿瘤对治疗的应答概率，癌度为大家做一下编译，希望对大家有所参考。

免疫细胞中的PD-1：免疫正常化的关键靶标

文章介绍 PD-1 在多种免疫细胞及肿瘤细胞中表达及作用，关乎免疫平衡与疾病进展，PD-1 抑制剂有成效，需深入研究以提升免疫治疗疗效。

带你深入了解PD-1

本文介绍 PD-1 的发现历程、信号通路、与配体作用方式及功能，阐述其在癌症免疫治疗中的应用及新用途，如在新辅助治疗中的效果，强调对其深入研究有助于更好应用于不同患者群体。